Biopharma dealmaking in mid-2026 continues to set pace, with reporting citing a record-breaking first half of M&A value through June. Separately, Dimerix acquired Mission Therapeutics’ acute kidney injury program, paying $5 million upfront with up to $287 million in milestone commitments for a Phase 2-ready candidate. Finally, a separate acquisition in diagnostics expands the pathology footprint: Danaher’s Leica Biosystems agreed to buy Statlab Medical Products, with analysts valuing the deal at more than $1 billion. Taken together, the moves show both portfolio consolidation for late-stage development and bolt-on capabilities in diagnostics supply chains.